Delcath Systems, Inc. (DCTHD) Rating Lowered to Sell at ValuEngine
Delcath Systems, Inc. (OTCMKTS:DCTHD) was downgraded by equities research analysts at ValuEngine from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Tuesday.
Shares of Delcath Systems (OTCMKTS DCTHD) traded down $0.12 during trading on Tuesday, hitting $1.13. The company’s stock had a trading volume of 408,347 shares, compared to its average volume of 78,739. Delcath Systems has a one year low of $0.96 and a one year high of $1,015.02.
An institutional investor recently raised its position in Delcath Systems stock. Vanguard Group Inc. increased its position in shares of Delcath Systems, Inc. (OTCMKTS:DCTHD) by 207.0% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,285,679 shares of the medical device company’s stock after purchasing an additional 866,838 shares during the period. Vanguard Group Inc. owned 1.09% of Delcath Systems worth $253,000 at the end of the most recent quarter. 7.97% of the stock is owned by hedge funds and other institutional investors.
About Delcath Systems
Delcath Systems, Inc is a late-stage clinical development company with early commercial activity in Europe focused on cancers of the liver. The Company is a specialty pharmaceutical and medical device company developing its product, Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System (Melphalan/HDS).
Receive News & Ratings for Delcath Systems Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Delcath Systems Inc. and related companies with MarketBeat.com's FREE daily email newsletter.